Literature DB >> 26275366

Delayed leukoencephalopathy of non-small cell lung cancer patients with brain metastases underwent whole brain radiation therapy.

Xiaoling Zhong1,2, Biao Huang3, Jieying Feng1, Wanqun Yang1, Hongjun Liu1.   

Abstract

To explore the incidence, MR imaging findings, dynamic developing process of delayed leukoencephalopathy (DLE) in non-small cell lung cancer (NSCLC) patients with brain metastases patients who undergone whole brain radiation (WBRT) therapy, we retrospectively reviewed 48 NSCLC patients who underwent WBRT for brain metastases from January 2010 through June 2015 and had evaluable magnetic resonance imaging after treatment. The DLE were graded using a scale to evaluate T2-FLAIR (fluid attenuated image recovery) images: grade 1 = little or no white matter hyperintensity, grade 2 = limited periventricular hyperintensity and grade 3 = diffuse white matter hyperintensity. 48 NSCLC patients with brain metastases were enrolled. The median age of these patients was 55.7 years (range 33-75 years). The median follow-up was 12 months. The characteristic MR imaging of DLE in those patients was bilaterally diffuse white matter T2 hyperintensity around the periventricular areas without enhancement, sparing from U-fiber, callosum and gray matter structure. The incidence of DLE developed 6.25% (3/48), 30.00% (12/40), 48.39% (15/31), 61.90% (13/21), 85.71% (6/7), 100% (3/3) in those patients who were followed up for 3, 6, 9, 12, 24, 36 months, respectively. Through increased understanding of it, it may be possible to help clinicians develop further therapeutic strategies to maximize benefit while limiting potential long term toxicities. These data supplement existing reports regarding the late effects of WBRT in NSCLC patients with brain metastasis.

Entities:  

Keywords:  Brain metastases; Delayed leukoencephalopathy; MRI; Non-small cell lung cancer; Whole brain radiation therapy

Mesh:

Year:  2015        PMID: 26275366     DOI: 10.1007/s11060-015-1888-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.

Authors:  Hidefumi Aoyama; Masao Tago; Norio Kato; Tatsuya Toyoda; Masahiro Kenjyo; Saeko Hirota; Hiroki Shioura; Taisuke Inomata; Etsuo Kunieda; Kazushige Hayakawa; Keiichi Nakagawa; Gen Kobashi; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-01       Impact factor: 7.038

2.  Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer.

Authors:  Edward A Monaco; Amir H Faraji; Oren Berkowitz; Phillip V Parry; Uri Hadelsberg; Hideyuki Kano; Ajay Niranjan; Douglas Kondziolka; L Dade Lunsford
Journal:  Cancer       Date:  2012-06-15       Impact factor: 6.860

3.  Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.

Authors:  Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner
Journal:  Neuro Oncol       Date:  2013-08-16       Impact factor: 12.300

Review 4.  The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases.

Authors:  P C Burger; M S Mahley; L Dudka; F S Vogel
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

5.  Incidence of leukoencephalopathy after whole-brain radiation therapy for brain metastases.

Authors:  Junko Ebi; Hisashi Sato; Masaru Nakajima; Fumio Shishido
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-23       Impact factor: 7.038

6.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

Review 7.  Radiation response of the central nervous system.

Authors:  T E Schultheiss; L E Kun; K K Ang; L C Stephens
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

8.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

9.  A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916).

Authors:  L T Komarnicky; T L Phillips; K Martz; S Asbell; S Isaacson; R Urtasun
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-01       Impact factor: 7.038

Review 10.  Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target.

Authors:  J S Wefel; A E Kayl; C A Meyers
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

View more
  5 in total

1.  Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial.

Authors:  Anthony Pham; Menachem Z Yondorf; Bhupesh Parashar; Ronald J Scheff; Susan C Pannullo; Rohan Ramakrishna; Philip E Stieg; Theodore H Schwartz; A Gabriella Wernicke
Journal:  J Neurooncol       Date:  2015-12-09       Impact factor: 4.130

Review 2.  Imaging findings in radiation therapy complications of the central nervous system.

Authors:  Tomonori Kanda; Yuichi Wakabayashi; Feibi Zeng; Yoshiko Ueno; Keitaro Sofue; Takaki Maeda; Munenobu Nogami; Takamichi Murakami
Journal:  Jpn J Radiol       Date:  2018-07-24       Impact factor: 2.374

3.  Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer.

Authors:  Yasuhiro Chikaishi; Masatoshi Kanayama; Akihiro Taira; Yusuke Nabe; Shinji Shinohara; Taiji Kuwata; Masaru Takenaka; Soichi Oka; Ayako Hirai; Koji Kuroda; Naoko Imanishi; Yoshinobu Ichiki; Fumihiro Tanaka
Journal:  Ann Transl Med       Date:  2018-10

Review 4.  Single isocenter stereotactic irradiation for multiple brain metastases: current situation and prospects.

Authors:  Megumi Uto; Daichi Torizuka; Takashi Mizowaki
Journal:  Jpn J Radiol       Date:  2022-09-03       Impact factor: 2.701

5.  Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy.

Authors:  Megumi Uto; Kengo Ogura; Tomohiro Katagiri; Keiichi Takehana; Takashi Mizowaki
Journal:  Radiat Oncol       Date:  2021-07-28       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.